Jagged1 heterozygosity in mice results in a congenital cholangiopathy which is reversed by concomitant deletion of one copy of Poglut1 (Rumi)

Shakeel M. Thakurdas, Mario F. Lopez, Shinako Kakuda, Rodrigo Fernandez‐Valdivia, Neda Zarrin‐Khameh, Robert S. Haltiwanger, Hamed Jafar‐Nejad – 1 August 2015 – Haploinsufficiency for the Notch ligand JAG1 in humans results in an autosomal‐dominant, multisystem disorder known as Alagille syndrome, which is characterized by a congenital cholangiopathy of variable severity.

Fibroblast growth factor receptor 3 isoforms: Novel therapeutic targets for hepatocellular carcinoma?

Jakob Paur, Lisa Nika, Christiane Maier, Alexander Moscu‐Gregor, Julia Kostka, Daniela Huber, Thomas Mohr, Petra Heffeter, Waltraud C. Schrottmaier, Sonja Kappel, Daniela Kandioler, Klaus Holzmann, Brigitte Marian, Walter Berger, Michael Grusch, Bettina Grasl‐Kraupp – 1 August 2015 – Fibroblast growth factor receptors (FGFRs) are frequently up‐regulated in subsets of hepatocellular carcinoma (HCC). Here, we provide mechanistic insight that FGFR3 splice variants IIIb and IIIc impact considerably on the malignant phenotype of HCC cells.

Chemokine (C‐X‐C motif) receptor 3–positive B cells link interleukin‐17 inflammation to protumorigenic macrophage polarization in human hepatocellular carcinoma

Rui‐Xian Liu, Yuan Wei, Qiu‐Hui Zeng, Ka‐Wo Chan, Xiao Xiao, Xiao‐Yu Zhao, Min‐Min Chen, Fang‐Zhu Ouyang, Dong‐Ping Chen, Limin Zheng, Xiang‐Ming Lao, Dong‐Ming Kuang – 1 August 2015 – B cells consistently represent abundant cellular components in tumors; however, direct evidence supporting a role for B cells in the immunopathogenesis of human cancers is lacking, as is specific knowledge of their trafficking mechanisms.

De novo hepatic steatosis drives atherogenic risk in liver transplantation recipients

Michael O. Idowu, Ravi Chhatrala, M. Bilal Siddiqui, Carolyn Driscoll, R. Todd Stravitz, Arun J. Sanyal, Chandra Bhati, Carol Sargeant, Velimir A. Luketic, Richard K. Sterling, Melissa Contos, Scott Matherly, Puneet Puri, M. Shadab Siddiqui – 30 July 2015 – Nonalcoholic fatty liver disease is associated with cardiovascular disease (CVD) in the general population. Despite a high prevalence of de novo hepatic steatosis after liver transplantation (LT), there are no data exploring the association between hepatic steatosis after LT and atherogenic risk.

Randomized, controlled trial of entecavir versus placebo in children with hepatitis B envelope antigen–positive chronic hepatitis B

Maureen M. Jonas, Mei‐Hwei Chang, Etienne Sokal, Kathleen B. Schwarz, Deirdre Kelly, Kyung Mo Kim, Simon C. Ling, Philip Rosenthal, Dumitru Oraseanu, Laurie Reynolds, Alexandra Thiry, Peter Ackerman – 29 July 2015 – This ongoing, randomized phase III study assesses the safety and efficacy of entecavir versus placebo in nucleos(t)ide‐naïve children (2 to <18 years) with hepatitis B envelope antigen (HBeAg)‐positive chronic hepatitis B (CHB). Blinded treatment was administered for a minimum of 48 weeks.

The UK‐PBC risk scores: Derivation and validation of a scoring system for long‐term prediction of end‐stage liver disease in primary biliary cholangitis

Marco Carbone, Stephen J. Sharp, Steve Flack, Dimitrios Paximadas, Kelly Spiess, Carolyn Adgey, Laura Griffiths, Reyna Lim, Paul Trembling, Kate Williamson, Nick J. Wareham, Mark Aldersley, Andrew Bathgate, Andrew K. Burroughs, Michael A. Heneghan, James M. Neuberger, Douglas Thorburn, Gideon M. Hirschfield, Heather J. Cordell, Graeme J. Alexander, David E.J. Jones, Richard N. Sandford, George F.

Aspartate aminotransferase to platelet ratio and fibrosis‐4 as biomarkers in biopsy‐validated pediatric cystic fibrosis liver disease

Daniel H. Leung, Mahjabeen Khan, Charles G. Minard, Danielle Guffey, Louise E. Ramm, Andrew D. Clouston, Gregory Miller, Peter J. Lewindon, Ross W. Shepherd, Grant A. Ramm – 29 July 2015 – Up to 10% of cystic fibrosis (CF) children develop cirrhosis by the first decade. We evaluated the utility of two simple biomarkers, aspartate aminotransferase to platelet ratio index (APRI) and FIB‐4, in predicting degree of fibrosis in pediatric CF liver disease (CFLD) validated by liver biopsy.

Subscribe to